Status:
UNKNOWN
Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome
Lead Sponsor:
Korea University Anam Hospital
Conditions:
Clinical Trial
Acute Coronary Syndrome
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
This study aimed to investigate the impact of intensive cholesterol-lowering therapy (including evolocumab), drug treatment for high-risk plaques (Vulnerable plaques) with a high probability of develo...
Eligibility Criteria
Inclusion
- Over 19 years old
- Patients who agree to the study plan and clinical follow-up plan, voluntarily decide to participate in this study, and consent in writing to the consent to use information
- Patients who underwent NIRS-IVUS guided coronary stent surgery for acute coronary syndrome
- Patients who did not meet the LDL-Cholesterol level (\<70mg/dL) even after receiving the maximum dose of combined cholesterol therapy for 2 months
Exclusion
- Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.)
- Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
- Subjects who plan to have surgery to stop antiplatelet drugs within 12 months from registration
- Those whose surviving life is expected to be less than 1 year
- Subjects who visited the hospital due to psychogenic shock and are predicted to have low survival probability based on medical judgment
- Subjects participating in a randomized study on cholesterol therapy
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04719221
Start Date
March 1 2021
End Date
December 1 2024
Last Update
October 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Anam Hospital
Seoul, South Korea